title: Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
abstract: Rifampin is a cornerstone of modern antituberculosis therapy. However, rifampin's half-life of 3 h is believed to limit its utility for intermittent therapy, so new congeners with long half-lives are being developed. Using an in vitro pharmacokinetic-pharmacodynamic model of tuberculosis, we examined the relationships between rifampin exposure, microbial killing of log-phase-growth Mycobacterium tuberculosis, and suppression of resistance. Rifampin's microbial killing was linked to the area under the concentration-time curve-to-MIC ratio. The suppression of resistance was associated with the free peak concentration (C(max))-to-MIC ratio and not the duration that the rifampin concentration was above MIC. Rifampin prevented resistance to itself at a free C(max)/MIC ratio of > or =175. The postantibiotic effect duration was > or =5.2 days and was most closely related to the C(max)/MIC ratio (r(2) = 0.96). To explain rifampin's concentration-dependent effect, we examined the kinetics of rifampin entry into M. tuberculosis. Rifampin achieved concentration-dependent intracellular steady-state concentrations within 15 min. Our results suggest that doses of rifampin higher than those currently employed would optimize the effect of rifampin, if patients could tolerate them. Another major implication is that in the design of new rifampin congeners for intermittent therapy, the important properties may include (i) the efficient entry of the rifamycin into M. tuberculosis, (ii) the achievement of a free C(max)/MIC of >175 that can be tolerated by patients, and (iii) a long postantibiotic effect duration.
authors.affiliation: Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9113, USA. Tawanda.Gumbo@UTSouthwestern.edu
authors.forename: Tawanda
authors.initials: T
authors.lastname: Gumbo
authors.forename: Arnold
authors.initials: A
authors.lastname: Louie
authors.forename: Mark R
authors.initials: MR
authors.lastname: Deziel
authors.forename: Weiguo
authors.initials: W
authors.lastname: Liu
authors.forename: Linda M
authors.initials: LM
authors.lastname: Parsons
authors.forename: Max
authors.initials: M
authors.lastname: Salfinger
authors.forename: George L
authors.initials: GL
authors.lastname: Drusano
mesh_terms: D000904:Antibiotics, Antitubercular / Q000493:pharmacokinetics / Q000494:pharmacology; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism; D012293:Rifampin / Q000493:pharmacokinetics / Q000494:pharmacology*; D013696:Temperature; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000904:Antibiotics, Antitubercular; D012293:Rifampin